Cyclooxygenase-2 expression is not associated with clinical outcome in synovial sarcoma

Oncology Reports

Volumn 26, Issue 6, 2011, Pages 1513-1517

  Carmody Soni, Emily E ^a   Miller, Benjamin J ^a   Scarborough, Mark T ^a   Reith, John ^a   Gibbs, C Parker ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cyclooxygenase 2; Immunohistochemistry; Prognosis; Synovial sarcoma

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LUNG METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SYNOVIAL SARCOMA;

ADOLESCENT; ADULT; AGED; CHILD; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS; YOUNG ADULT;

EID: 80053518938     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1431     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Eilber FC and Dry SM: Diagnosis and management of synovial sarcoma. J Surg Oncol 97: 314-320, 2008.
3. Lewis JJ, Antonescu CR, Leung DHY, et al: Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 18: 2087-2094, 2000.
4. Spillane AJ, A'Hern R, Judson IR, et al: Synovial sarcoma: a clinicopathologic, staging and prognostic assessment. J Clin Oncol 18: 3794-3803, 2000.
5. Ferrari A, Gronchi A, Casanova M, et al: Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101: 627-634, 2004.
6. Mullen JR and Zagars GK: Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol 33: 23-30, 1994.
7. Ryan JR, Baker LH and Benjamin RS: The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology Group. Clin Orthop Relat Res 164: 257-260, 1982.
8. Skinner KA and Eilber FR: Soft tissue sarcoma nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5: 121-127, 1996.
9. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al: Synovial sarcoma: identification of low and high risk groups. Cancer 85: 2596-2607, 1999.
10. Golouh R, Vuzevski V, Bracko M, et al: Synovial sarcoma: a clinicopathologic study of 36 cases. J Surg Oncol 45: 20-28, 1990.
11. Oda Y, Hashimoto H, Tsuneyoshi M, et al: Survival in synovial sarcoma: a multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol 17: 35-44, 1993.
12. Pisters WT, Leung DHY, Woodruff J, Shi W and Brennan MF: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14: 1679-1689, 1996.
13. Gortzak E, Azzarelli A, Buesa J, et al: A randomized phase II study on neoadjuvant chemotherapy for 'high-risk' adult soft tissue sarcoma. Eur J Cancer 37: 1096-1103, 2001.
14. Italiano A, Penel N, Robin YM, Bui B, Le Cesne A, Piperno-Neumann S, Tubiana-Hulin M, Bompas E, Chevreau C, Isambert N, Leyvraz S, du Chaterlard PP, Thyss A, Coindre JM and Blay JY: Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 20: 425-430, 2009.
15. McCarter MD, Jaques DP and Brennan MF: Randomized clinical trials in soft tissue sarcoma. Surg Oncol Clin N Am 11: 11-22, 2002.
16. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
17. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
18. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogensis induced by colon cancer cells. Cell 93: 705-716, 1998.
19. Attiga FA, Fernandez PM, Weeraratna AT, et al: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637, 2000.
20. Tsujii M and Du Bois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
21. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cylclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
22. Chan G, Boyle JO, Yang EK, et al: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999.
23. Kulkarni S, Rader JS, Zhang F, et al: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7: 429-434, 2001.
24. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinoma. Cancer Res 58: 3761-3764, 1998.
25. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
26. Dickens DS, Kozielski R, Khan J, Forus A and Cripe TP: Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 5: 356-364, 2002.
27. Masi L, Recenti R, Silvestri S, Pinzani P, Pepi M, Paglierani M, Brandi ML and Franchi A: Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol 15: 70-76, 2007.
28. Sutton KM, Wright M, Fondren G, Towle CA and Mankin HJ: Cyclooxygenase-2 expression in chondrosarcoma. Oncology 66: 275-280, 2004.
29. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW and Dannenberg AJ: Celocoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer. J Clin Oncol 21: 2645-2650, 2003.
30. Dang CT, Shapiro CL, Solove RJ and Hudis CA: Potential role of selective COX-2 inhibitors in cancer management. Oncology 16: 30-36, 2002.
31. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K and Sakurai K: Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 23: 665-672, 2003.
32. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M and Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6: 2006-2011, 2000.
33. Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodriguez-Bigas M, Su L-K, Sherman J, Kelloff G, Levin B and Steinbach G: A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Cancer 50: 857-860, 2002.
34. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L-K and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
35. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K and DuBois RN: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266, 2005.
36. Endo I, Matsumura T, Yamaguchi T, Yamaguchi U, Morimoto Y, Nakatani F, Kawai A, Chuman H, Beppu Y, Shimoda T and Hasegawa T: Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcoma. Hum Pathol 37: 471-476, 2006.
37. Takatori H, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Tamotsu K, Owaki T, Ishigami S and Aikou T: Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 34: 397-402, 2008.
38. Urakawa H, Nishida Y, Naruse T, Nakashima H and Ishiguro N: Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res 467: 2932-2938, 2009.
39. Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, Hawkins DS, Munsell MF and Kleinerman ES: COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol 30: 507-512, 2008.
40. Dickens DS, Kozielski R, Leavey PJ, Timmons C and Cripe TP: Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 25: 282-285, 2003.
41. Lassus P, Ristimaki A, Huuhtanen R, Tukiaimen E, Asko-Seljavaard S, Andersson LC, Miettinen M, Blomquist C, Haglund C and Bohling T: Cyclooxygenase-2 expression in human soft tissue sarcoma is related to epithelial differentiation. Anticancer Res 25: 2669-2674, 2005.
42. Herceg ME, Tsiatis AC, Halpern JL, Holt GE, Schwartz HS, Keedy VL and Cates JM: Cyclooxygenase-2 expression in soft tissue leiomyosarcoma. Anticancer Res 29: 2913-2917, 2009.